That passphrase isn't right. Check your invitation email, or contact harry.massey@e4l.com.
Confidential. For accredited investors only. Securities offered under Rule 506(c) of Regulation D; accredited status is verified before any subscription is accepted. Site access is granted by E4L, Inc.
Every figure on this page is generated from the quarterly model — system sales, practitioner counts, subscriber counts — never typed in by hand. FY2026 is a four-month partial year (September–December 2026, Q4 2026 — the first quarter of revenue), not a full year. Three headlines:
Revenue opens at $2.7M (Q4 2026, the first quarter of revenue — a partial period), reaches $16.0M in FY2027, the first full year, and grows to $134.7M by FY2031, built from six revenue lines.
Model v2.6 · quarterly CSV totalsThe plan turns EBITDA-positive in Q2 2027 and stays positive every quarter after — reaching a 29% margin by 2031.
Model v2.6 · EBITDA by quarterCash never drops below about $1.2M — the Q3 2026 low, between the two SAFE closes — and ends 2031 at $67.2M, after a blended ~25% tax provision (new in v2.6).
Model v2.6 · cash by quarter, after taxThree charts, straight from the quarterly model. Hover any bar or point for the exact figures; the full quarter-by-quarter table is below.
Six revenue lines stack to the total. FY2026 is the September–December partial year (Q4 2026, the first quarter of revenue).
“BWS systems” groups the model’s four system-revenue lines: upfront purchases, down payments, monthly rent-to-own payments, and early buyouts. *FY2026 = Sep–Dec partial year (Q4 2026, first quarter of revenue).
A short burn (three quarters, ~$0.58M in total), then profitable every quarter of the plan — a 29% EBITDA margin by 2031, after funding the Physics-First R&D reinvestment.
Q4 2026 is near breakeven (−$52,862); Q1 2027 dips slightly (−$115,198) as the Physics-First R&D reinvestment turns on, and the first sustained positive quarter is Q2 2027 (+$226,277).
The $5M SAFE (Sep–Nov 2026) is the only financing in the plan — no further raise is assumed. Cash here is after a blended ~25% income-tax provision on profits (v2.6) — the model also carries depreciation, amortization of the acquired intangibles, and a full cash-flow statement and balance sheet. From 2027 we reinvest a growing, disciplined share of cash into R&D — see The Upside.
Low point across the whole plan: $1,213,962 in Q3 2026 — after the $1.8M first close, before the $3.2M balance lands. These are ordinary rolling closings of one $5M round on identical terms — not investment tranching or milestone-gated draws; the money comes in as investors sign.
Contingent sensitivity — the Stoneburner put. Kitty Stoneburner (Healing Frequencies LLC), an early investor, holds a right, exercisable only in a 1–15 September 2026 window, to sell her shares back to the company for $1,729,111.34 paid over 24 monthly installments. The base case assumes she keeps her equity, so it is not in the numbers above. If she elects, the Stoneburner put is funded by a separate ~$2M raise and/or Harry's backstop loan — not from the SAFE investors' capital; the modelled cash balance absorbs the installments and stays positive in every quarter (lowest point ~$2.6M in Q2 2027), with Harry personally guaranteeing and loaning the payments only if and while cashflow can’t cover them.
| Quarter | Practitioner wholesale | BWS systems | miHealth devices | GEM hardware | Consumer infoceuticals | App subscriptions | Total revenue | EBITDA | Cash (end) |
|---|
The whole forecast is these six assumptions compounding. Change them and the numbers change — that is the point of the open model.
A practitioner takes the Bioenergetic Wellness System for $3,997 down + $397/month for 60 months — or buys it outright for $20,000. About 60% of renters buy out early (around month 12), paying $20,000 minus everything they’ve already paid.
New system sales start at 10 a month (Sep 2026), reach 20 by December and 30 by March 2027, then grow steadily to ~124 a month by end-2031. Each salesperson closes about four systems a month.
Every active practitioner buys consumables wholesale: about $450 a month today, rebuilding to $600 over the plan. The historical peak was $720 — so $600 is a return, not a stretch.
~650 acquired practitioners buy consumables from day one; only ~100 of them still have active system payment streams. Churn across the whole base: 8% a year.
The GEM scanner at $397 feeds app subscriptions at $9.99 or $29.99 a month, plus Cell Driver+ at $38 a month delivered — grown by paid media and the Beyond Medicine film.
One $5M SAFE, landing September–November 2026 ($1.8M then $3.2M). No further financing is assumed anywhere in the plan.
So the consumer number isn’t a black box, these are the model’s stated assumptions (not results): paid traffic at ~$2 CPC held flat; a ~1–2% purchase conversion (the model starts at 1.0% and treats 2.0% as an unreached ceiling); ~60% app-subscription attach after the trial; and an ~8-month initial subscription retention that improves over the plan. Change any of them in the open model and the consumer line moves.
Cut both key drivers — practitioner system sales and consumer conversion — by 30%, and change nothing else: revenue is still $12.5M in 2027 and $95.5M in 2031, FY2029 EBITDA is still +$3.1M, and cash stays positive with zero spending cuts (the same ~$1.2M low, before the drivers even diverge). The exposure in this plan is growth, not solvency.
An honest break case. Beyond the −30% sensitivity: if the film funnel underperforms and practitioner reactivation lags, the consumer and new-practitioner lines are materially slower than modelled. In that case the acquired wholesale base and existing practitioner revenue are the floor the business rests on — slower growth, but the recurring base remains.
Upside not modeled. These numbers exclude licensing revenue from mapping the body’s energy field — deliberately, to keep the forecast conservative. That potential is described in the Overview page’s The Upside section; no figure from it flows into any total here.
Assumptions under review — three inputs still carry an amber flag in the model and are being confirmed: [TBC — Harry] rent-to-own vs upfront mix (80/20), [TBC — Harry] early-buyout timing (~month 12), [TBC — Harry] base buyout mechanics. The charts above use the stated defaults; none of the three changes the shape of the plan.
Projections are management assumptions, not promises. Prepared August 2026 from the bottoms-up model (v2.6).